Three Key Concepts When Initiating Opioid Therapy
What insurance claims managers should expect from treating doctors when opioids are first prescribed.
Published: 4 April 2026
Introduction
When your claimant's treating doctor proposes opioid therapy, three fundamental concepts should guide that decision. As an insurance claims manager, you need to understand what these concepts mean, what documentation should support them, and what red flags suggest a provider is not following best practice.
The three key concepts are: comprehensive patient selection and risk assessment; informed consent and treatment agreement; and documented monitoring plan. When these three elements are present and well-documented, you can have confidence that opioid therapy initiation is thoughtful and appropriate. When these elements are absent or inadequately documented, you have grounds to question the decision.
Concept 1: Patient Selection and Risk Assessment
What This Means
Before opioids are initiated, your treating provider should have conducted a comprehensive assessment to determine whether opioid therapy is appropriate for this specific patient. This assessment goes beyond the pain complaint; it examines the patient's overall medical, psychological, and social context to identify risk factors that might make opioids inadvisable or require special precautions.
What Good Patient Selection Looks Like
A well-documented patient selection process includes:
- Clear diagnosis: The treating provider has established a clear pain diagnosis and documented what has been tried previously. They have excluded conditions where opioids would be inappropriate (such as certain headache disorders).
- Non-opioid interventions attempted first: For most chronic pain conditions, guidelines recommend trying non-opioid and non-medication treatments first. Documentation should show that physical therapy, other medications, or psychological approaches have been offered or attempted.
- Baseline pain and functional assessment: The provider has documented baseline pain levels (using a standardized scale such as 0-10) and baseline function. This establishes the starting point against which improvement will be measured.
- Substance use history: The provider has specifically asked about and documented current and past substance use, including alcohol, illicit drugs, and misuse of prescription medications. This is critical for identifying patients at higher risk of opioid misuse.
- Mental health screening: Depression, anxiety, and post-traumatic stress disorder are common in populations with chronic pain and increase opioid misuse risk. Documentation should include screening for these conditions and, where indicated, assessment by mental health specialists.
- Medication history: The provider has reviewed current medications to identify drugs that interact with opioids (especially benzodiazepines and other sedating agents) and documented a plan for managing these interactions.
- Structured risk assessment tool: Many pain specialists use formal risk assessment tools such as the Opioid Risk Tool (ORT) or SOAPP-R scale. Using a structured tool demonstrates systematic risk evaluation.
Red Flags in Patient Selection
Watch for these signs that patient selection may have been inadequate:
| Red Flag | What It Suggests | Your Action |
|---|---|---|
| Opioids initiated without documented attempt at non-opioid treatments | Provider skipped required step of trialling alternatives first | Request documentation of why non-opioid approaches were not attempted |
| No baseline pain or function scores recorded before starting opioids | No objective measure of what therapy is supposed to improve | Request baseline assessments to establish treatment goals |
| No substance use history documented | Provider did not assess a key risk factor for opioid misuse | Request structured substance use assessment before continuing opioids |
| Opioids initiated in patient with active substance use disorder | High-risk prescribing without documented risk mitigation | Request structured addiction medicine input and intensive monitoring plan |
| No mental health assessment despite chronic pain diagnosis | Missing critical component of risk assessment | Request mental health screening and psychological input before continuing |
| Concurrent benzodiazepine use not addressed | High-risk drug combination without documented risk mitigation | Request plan for benzodiazepine taper or documented high-risk monitoring protocol |
Concept 2: Informed Consent and Treatment Agreement
What This Means
Informed consent means your patient understands the key risks and benefits of opioid therapy and has explicitly agreed to proceed. A treatment agreement documents the terms under which opioids will be provided, including your patient's responsibilities and the consequences of non-compliance.
What Good Informed Consent Looks Like
Documentation of informed consent should include evidence that the patient has been counseled on:
- Benefits and goals: What pain reduction is expected, what functional improvements are hoped for, and realistic timelines for improvement.
- Addiction risks: The potential for physical dependence and addiction, including that addiction can occur even when taking medication as prescribed. This discussion should be explicit and documented.
- Overdose risk: Particularly the increased overdose risk if benzodiazepines or other sedating drugs are used concurrently. The patient should understand that overdose can be fatal.
- Side effects: Common side effects including constipation, sedation, cognitive effects, and nausea. The patient should understand that side effects may persist or require management strategies.
- Driving and safety: Opioids can impair driving and other complex activities. The patient should be counseled on safety implications.
- Alternatives to opioids: The provider has discussed why opioids are being chosen instead of or in addition to alternative approaches.
What a Good Treatment Agreement Includes
A treatment agreement should address:
- Specific opioid medication, dose, and frequency prescribed
- That doses should not be changed without provider discussion and consent
- That the medication is for the patient only and must not be shared
- Safe storage requirements to prevent access by others, particularly children
- Requirement for monitoring appointments at specified intervals
- Requirement for urine drug screening at baseline and regular intervals
- Agreement not to obtain opioids from other providers without disclosing to this provider
- Restrictions on concurrent benzodiazepine or other sedating drug use
- Consequences of non-compliance, including potential discontinuation of opioid therapy
- That the patient has had opportunity to ask questions and has understood the agreement
Red Flags in Informed Consent and Treatment Agreements
Warning Signs That Consent May Be Inadequate
- No documentation of consent discussion
- Vague or generic consent forms not specific to opioid therapy
- No documented discussion of addiction potential or overdose risk
- Consent obtained under time pressure or with limited opportunity for questions
- No treatment agreement despite initiating controlled-release or high-dose opioids
- Treatment agreement present but not signed by patient or not reviewed with patient
- Opioids escalated to high doses without re-consenting for increased risk
Concept 3: Documented Monitoring Plan
What This Means
Before opioids are initiated, the provider should have articulated a plan for monitoring how the patient responds to treatment. This plan specifies what will be measured, how often assessments will occur, and what will trigger treatment modification.
What a Good Monitoring Plan Includes
A documented monitoring plan should specify:
- Outcome measures: How pain and function will be measured. This might reference the 5 A's framework or other structured outcome tools. Specific pain scales and functional capacity measures should be identified.
- Monitoring frequency: How often the patient will be assessed. Typical schedules involve in-person review every 4-8 weeks during the initiation phase, with ongoing regular reviews for continuing therapy.
- Assessment tools for safety: The plan should specify how side effects will be monitored, how substance use will be screened (including urine drug screening frequency), and how mental health will be assessed.
- Real-time prescription monitoring: The plan should specify that SafeScript (or state equivalent) will be checked before initiation and at regular intervals to detect multiple-prescriber presentations or other concerning patterns.
- Involvement of other providers: If the patient is seeing other specialists, the plan should address how communication and coordination will occur to ensure no gaps in care.
- Dose adjustment triggers: The plan should specify what outcomes (pain reduction, function improvement, adverse effects, aberrant behaviour) will trigger dose changes.
- Exit criteria: The plan should address conditions under which opioid therapy would be discontinued or modified (for example, persistent non-compliance, emergence of substance use disorder, or lack of therapeutic benefit).
Red Flags in Monitoring Plans
Be cautious when:
- No monitoring plan is documented
- Monitoring is scheduled at vague intervals such as "as needed" or "periodically"
- No objective outcome measures are specified
- No mention of substance use screening or urine drug testing
- No mention of mental health monitoring
- No mention of SafeScript checking or other prescription monitoring
- Plan mentions monitoring but early review notes show no documented assessments occurring at planned intervals
- No clear criteria for what would prompt treatment modification
Practical Claims Management: Using These Three Concepts
When Reviewing an Opioid Initiation Decision
When you receive documentation of opioid therapy initiation, systematically review whether documentation addresses all three concepts:
- Do the medical records show evidence of comprehensive patient selection and risk assessment?
- Is there documented informed consent that addresses key opioid risks?
- Is there a clear, documented monitoring plan?
If the answer to any of these is "no" or "unclear," you have legitimate grounds to request additional documentation or to request a structured medication review before approving ongoing opioid therapy.
When Requesting Treatment Modification
If you're requesting that treatment be modified or reviewed, reference these three concepts in your communication with the treating provider: "I notice the medical records do not include documented informed consent discussion regarding addiction risk" or "The monitoring plan does not specify how substance use will be screened, yet the patient has significant substance use history."
This approach is more professional and evidence-based than subjective concerns about opioid use.
Need independent assessment of whether your claimant's opioid initiation followed best practice?
IMM provides detailed medication reviews that evaluate whether treatment initiation included proper patient selection, informed consent, and monitoring plan documentation. Our pharmacists identify gaps and recommend next steps.
Request an IMM Medication ReviewConclusion
When opioid therapy is initiated thoughtfully, using these three key concepts as your framework, you're likely to see better long-term outcomes. Patient selection ensures appropriate patients are chosen. Informed consent ensures they understand the risks. Documented monitoring plans ensure treatment is tracked against measurable outcomes.
As an insurance claims manager, these three concepts give you a practical way to assess whether opioid therapy initiation was done well. When all three are present and well-documented, you can support the treatment with confidence. When they're absent, you have clear grounds to request additional assessment or modification.
